Form 4: Guardant Health's Chief Medical Officer, Craig Eagle, Reports Stock Transactions
SEC Form 4 Filing
Craig Eagle, Chief Medical Officer of Guardant Health, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 1, 2025, Craig Eagle, the Chief Medical Officer of Guardant Health, had 5,686 shares of common stock acquired through the vesting of performance-based restricted stock units.
- Also on March 1, 2025, 2,029 shares were disposed of to cover tax withholding obligations at a price of $42.55 per share.
- Following these transactions, Eagle directly owns 29,613 shares of common stock.
- He also holds 11,376 performance-based restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock transactions. The vesting of stock units based on performance is a slightly positive indicator.
Positives
- The vesting of restricted stock units indicates that performance metrics were achieved, which is a positive signal.
Future Outlook
The remaining 67% of the performance-based restricted stock units will vest over the following two years, with 33% vesting on January 1, 2026, and 34% vesting on January 1, 2027.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives. This filing indicates standard compensation practices at Guardant Health.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the biotechnology industry, used to align the interests of executives with those of shareholders.
- Companies like Illumina, Roche, and Exact Sciences also utilize restricted stock units as part of their executive compensation packages.
- The vesting schedules and performance metrics associated with these awards vary by company and individual circumstances.
Stakeholder Impact
- Shareholders may view the vesting of performance-based restricted stock units as a positive sign, indicating that performance goals are being met.
- Employees may be motivated by the potential for similar stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| February 26, 2024 | Date of grant for the performance-based restricted stock unit award. |
| March 1, 2025 | Date of stock vesting and tax withholding. |
| January 1, 2026 | Date when 33% of the remaining shares subject to the award vest. |
| January 1, 2027 | Date when 34% of the remaining shares subject to the award vest. |
| March 4, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.